Phase 1 Study of Niclosamide in Pediatric Patients With Relapsed and Refractory AML
Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Protocol is designed to evaluate a niclosamide dose escalation scale in combination with
cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute
myeloid leukemia.